Gene-modified cell therapies such as CAR-T are promising to be revolutionary in their ability to treat hereditary and acquired diseases, especially cancer, and the demand for scalable and cost-effective methods to produce them is high. However, the production of these cells requires many time- and labor-intensive steps which leads to delays. Specifically, efficient viral vector production is essential in engineering T-cells to express CARs, so optimizing this step early on in development is critical. This application note describes how key components of the Sartorius T-Cell Screening Solution address this need and simplify CAR-T research workflows by enabling rapid and effective lentivirus clarification.

Complete The Form Below To Download The App Note

Complete The Form Below To Download The App Note